Sign in

    Evan Wang

    Vice President and Equity Research Analyst at Guggenheim Securities

    Evan Wang is a Vice President and Equity Research Analyst at Guggenheim Securities, specializing in the specialty hospitals sector and healthcare services. He covers several U.S. companies, including Spruce Biosciences and Invivyd, and his recent analyst performance is tracked by platforms like TipRanks, where he currently holds a low success rate with an average return of -53% over the past year on his published ratings. Wang began his investment research career at Guggenheim in 2020 as an Associate, was promoted to Vice President in April 2022, and previously interned at China Everbright Securities. He holds a Bachelor of Science in Finance and Statistics from New York University and is FINRA-registered with active securities licenses.

    Evan Wang's questions to Arcturus Therapeutics Holdings (ARCT) leadership

    Evan Wang's questions to Arcturus Therapeutics Holdings (ARCT) leadership • Q2 2025

    Question

    Evan Wang of Guggenheim Partners asked for the timing of fuller data from the OTC program and for commentary on the influenza vaccine's immune response relative to its comparator arm.

    Answer

    President and CEO Joseph Payne stated that detailed comparator data for the influenza vaccine will be released by their partner, CSL, at a later date. For the OTC program, the timing for fuller data depends on the final decision of whether to proceed with the 0.7 mg/kg dose cohort. The immediate focus is on achieving alignment with the FDA on the pivotal trial design in the first half of 2026.

    Ask Fintool Equity Research AI

    Evan Wang's questions to Moderna (MRNA) leadership

    Evan Wang's questions to Moderna (MRNA) leadership • Q3 2024

    Question

    Evan Wang asked about potential policy barriers to vaccine use under a new U.S. administration and the company's confidence in its ex-U.S. RSV vaccine competitiveness, given competitor commentary on data sufficiency.

    Answer

    CEO Stéphane Bancel stated that Moderna has always worked collaboratively with government leaders and will continue to do so, as its mission to improve public health aligns with any administration's goals. Regarding ex-U.S. RSV, he noted that the ramp-up is slower due to varied approval, recommendation, and pricing negotiation timelines in international markets.

    Ask Fintool Equity Research AI

    Evan Wang's questions to Invivyd (IVVD) leadership

    Evan Wang's questions to Invivyd (IVVD) leadership • Q1 2024

    Question

    Evan Wang of Guggenheim Securities asked for a framework on the development plan for the next-generation antibody VYD2311 and questioned how the PEMGARDA treatment opportunity fits into a market with established players like PAXLOVID.

    Answer

    Marc Elia, Chairman, stated that development pathways for new molecules like VYD2311 are being actively designed in collaboration with the FDA, building on the precedent set by PEMGARDA. Mark Wingertzahn, SVP of Clinical Development, positioned PEMGARDA as a valuable treatment option for immunocompromised patients, citing the burdens of remdesivir and the significant drug-drug interactions associated with PAXLOVID.

    Ask Fintool Equity Research AI

    Evan Wang's questions to Inventiva (IVA) leadership

    Evan Wang's questions to Inventiva (IVA) leadership • Q4 2021

    Question

    Evan Wang, on behalf of Seamus Fernandez at Guggenheim Securities, asked about the cedirogant (ROR-gamma) program. He sought details on the Phase I profile that provides confidence for the Phase IIb trial, its competitive positioning against other oral psoriasis treatments, and what other indications might be appropriate for this target.

    Answer

    Executive Pierre Broqua explained that while the Phase Ib data is not public, it was compelling enough for AbbVie to commit to a large, 200-patient Phase IIb study. He noted that AbbVie may present the data at a future conference. For other potential indications, he highlighted areas where IL-17 inhibition is relevant, such as psoriatic arthritis, ankylosing spondylitis, and potentially rheumatoid arthritis and ulcerative colitis, based on preclinical data.

    Ask Fintool Equity Research AI

    Evan Wang's questions to Boundless Bio (BOLD) leadership

    Evan Wang's questions to Boundless Bio (BOLD) leadership • Q4 2018

    Question

    Evan Wang of Guggenheim Securities LLC asked for a comparison of Audentes' manufacturing process with Spark Therapeutics and for details on recent interactions with the European Medicines Agency (EMA).

    Answer

    President and CEO Matthew Patterson highlighted that Audentes uses a robust and scalable serum-free suspension culture system at a 1000L scale, which is well-suited for neuromuscular diseases. He also noted that recent feedback from the EMA was highly consistent with the FDA's, suggesting a single data package could likely support regulatory filings in both regions.

    Ask Fintool Equity Research AI